Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
For chronic hepatitis C patients unresponsive to previous (PEG-)IFN/RBV combination therapy
we propose continuous subcutaneous administration of high-dose IFN-a2b (Intron A®) for 48
weeks in combination with 15 mg/kg/day RBV (Rebetol®) and optimal management of side effects
in order to maintain the highest possible dosages of both IFN-a2b and RBV for 48 weeks. We
expect improved tolerability with continuous subcutaneous pump delivery of IFN-a2b compared
to thrice weekly or daily subcutaneous injection of IFN-a2b, and increased antiviral activity
and biologic potency due to sustained and higher levels of a fully potent interferon protein.